The influence of HCV genotype on the IFN treatment of patients with chronic hepatitis C.
- Author:
Yao XIE
1
;
Dao-zhen XU
;
Zhi-meng LU
;
Kang-xian LUO
;
Ji-dong JIA
;
Yu-ming WANG
;
Gui-zhen ZHAO
;
Shu-lin ZHANG
;
Da-zhi ZHANG
Author Information
- Publication Type:Clinical Trial
- MeSH: Antiviral Agents; therapeutic use; Genotype; Hepacivirus; classification; genetics; Hepatitis C, Chronic; drug therapy; virology; Humans; Interferon-alpha; therapeutic use; Polyethylene Glycols; therapeutic use; Recombinant Proteins; Recurrence
- From: Chinese Journal of Hepatology 2004;12(2):72-75
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the influence of HCV genotype on the IFN treatment of patients with chronic hepatitis C.
METHODSThe genotypes of HCV virus were determined in the patients enrolled into the Randomized, opened and controlled trial of Peg-IFN alpha-2a (Pegasys) treatment, controlled with IFN-alpha-2a (Roferon-A), on chronic hepatitis C patients in China. The serum ALT levels and HCV RNA concentration of the patients were detected in the time of before treatment, the end of therapy and follow-up. The influence of HCV genotype on the IFN treatment of patients with chronic hepatitis C was analyzed in intention to treat (ITT) population.
RESULTSThe HCV genotypes of 202 cases were determined. 158 (78.2%) cases infected with genotype 1 HCV and 44 (21.8%) cases with genotype non-1. For overall patients, the viral response at the end of treatment (ETVR) and sustained viral response (SVR) rates were 53.8% and 25.3% respectively in patients with genotype 1 HCV, but in genotype non-1 patients those was 61.4% and 43.2%, and the difference of SVR between genotype 1 and non-1 was significant (P=0.021). After grouped by the used drugs, in the patients given Pegasys treatment, the ETVR rates of patients with genotype 1 and non-1 HCV infection were 76.8% and 81.0%, the difference was not significant (P=0.686), but the difference of SVR rates, which were 35.4% and 66.7%, of the patients was significant (P=0.01). The viral relapse rate of genotype 1 was 55.6%; it was significant higher than that of genotype non-1 (23.5%) (P=0.02). In Roferon-A group, the ETVR and SVR rates of patients with genotype 1 HCV were 29.0% and 14.5%, which were lower, but not significant, than those of patients with genotype non-1 (43.5% and 21.7%). The viral relapse rate of genotype 1 was 72.7% and higher, but not significant, than that of genotype non-1 also (50.0%) (P=0.21).
CONCLUSIONHCV genotype could affects the efficacies, mainly the sustained responses, of IFN treatment of patients with chronic hepatitis C, and the effects of IFN were related to the kinds of drugs and therapeutic course.
